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Abstract 
Motivation: Influenza A viral heterogeneity remains a significant threat due to unpredictable antigenic 
drift in seasonal influenza and antigenic shifts caused by the emergence of novel subtypes. Annual 
review of multivalent influenza vaccines targets strains of influenza A and B likely to be predominant 
in future influenza seasons. This does not induce broad, cross protective immunity against emergent 
subtypes. Better strategies are needed to prevent future pandemics. Cross-protection can be 
achieved by activating CD8+ and CD4+ T cells against highly-conserved regions of the influenza ge-
nome. We combine available experimental data with informatics-based immunological predictions to 
help design vaccines potentially able to induce cross-protective T-cells against multiple influenza sub-
types. 
Results: To exemplify our approach we designed two epitope ensemble vaccines comprising highly-
conserved and experimentally-verified immunogenic influenza A epitopes as putative non-seasonal 
influenza vaccines; one specifically targets the US population and the other is a universal vaccine. 
The USA-specific vaccine comprised 6 CD8+ T cell epitopes (GILGFVFTL, FMYSDFHFI, 
GMDPRMCSL, SVKEKDMTK, FYIQMCTEL, DTVNRTHQY) and 3 CD4+ epitopes 
(KGILGFVFTLTVPSE, EYIMKGVYINTALLN, ILGFVFTLTVPSERG). The universal vaccine com-
prised 8 CD8+ epitopes: (FMYSDFHFI, GILGFVFTL, ILRGSVAHK, FYIQMCTEL, ILKGKFQTA, 
YYLEKANKI, VSDGGPNLY, YSHGTGTGY) and the same 3 CD4+ epitopes. Our USA-specific vac-
cine has a population protection coverage (portion of the population potentially responsive to one or 
more component epitopes of the vaccine, PPC) of over 96% and 95% coverage of observed influen-
za subtypes. The universal vaccine has a PPC value of over 97% and 88% coverage of observed 
subtypes. 
Availability: http://imed.med.ucm.es/EPISOPT.html. 
Contact: d.r.flower@aston.ac.uk  
Supplementary information: none. 
 
 
1 Introduction  
Vaccines are the most efficacious and efficient medical intervention 
known. While vaccines based on inactivated or attenuated whole mi-
crobes or single protein subunits have proved widely useful, vaccines 
based on ensembles of epitopes remain underexploited. We have recently 
developed a powerful new approach to the design of epitope ensemble 
vaccines combining available experimental data with informatics-based 
immunological predictions (Molero-Abraham et al., 2013). This ap-
proach now begins to gain a gratifyingly widening acceptance as a vac-
cine design tool (Gededzha et al., 2014; Oany et al., 2015).  
Influenza is an infectious acute respiratory disease caused by single-
negative-strand RNA viruses of the family Orthomyxoviridae, within 
which three genera - Influenzavirus A, Influenzavirus B, and Influen-
zavirus C - contain viral strains corresponding to influenza types A, B 
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and C respectively (ICTV 2014; 
http://ictvonline.org/virusTaxonomy.asp). Transmission can occur 
through droplets, aerosol inhalation, and direct physical contact with 
infected hosts or contaminated surfaces (Weber & Stilianakis, 2008). 
Treatment when necessary includes antivirals to relieve symptoms and 
reduce complications. However, prevention through vaccination is cur-
rently the most effective strategy to combat influenza viruses (Schotsaert 
& Garcia-Sastre, 2014). 
Only influenza A has both seasonal epidemic and pandemic capability 
and is classified into subtypes according to its hemagglutinin (HA) and 
neuraminidase (NA) surface glycoprotein antigens (Zhang et al., 2015). 
Influenza A caused the Spanish (1918-1919); Asian (1957) and Hong 
Kong (1968) flu pandemics, which all led to global mortality in the mil-
lions (Kilbourne, 2006). Pandemic strains continue to circulate as sea-
sonal influenza maintained by antigenic drift where mutations occur on 
the antigenic binding sites of NA and HA. However, pandemic strains 
arise through antigenic shifts, where a completely new subtype emerges 
via gene re-assortment after distinct influenza viruses co-infect an inter-
mediate host.  
Seasonal Flu vaccines are mediated by antibody responses against NA 
and HA proteins, which unfortunately are highly variable; the large 
numbers of annual deaths continues to raise serious questions about the 
effectiveness of current vaccines and vaccination strategies (World 
Health Organisation [WHO], 2009; 
http://www.who.int/csr/don/2009_09_18/en/). Formulating a "universal 
vaccine" where multiple strains are targeted to induce so-called het-
erosubtypic immunity (HSI) may prove more effective in combating 
novel strains before they can go on to cause pandemics (Nguyen et al., 
2007). 
Studies in animal models have suggested that generating cellular immun-
ity via T cell responses may induce broad, cross-reactive protection that 
current vaccines apparently lack. T cells target exposed and non-exposed 
proteins that are processed and presented by Human Leukocyte Antigens 
(HLAs).  There are two main types of T cells: cytotoxic CD8+ T cell 
lymphocytes (CTLs) and CD4+. CTLs recognize antigens presented by 
HLA class I (HLA I) molecules while CD4 T cell recognize antigens 
presented by HLA class II (HLA II) molecules. The role of CTL in cellu-
lar immunity includes the direct clearance of virally infected cells and 
the indirect recruitment of other immune cells via chemokine and cyto-
kine secretion. CD4+ T cells' primary roles include B cell stimulation 
leading to specific antigen antibody production as well as stimulating 
CD8+ proliferation and memory responses. CD4+ T cells also mediate 
direct and indirect viral clearance, and symptom severity reduction in 
secondary infection (Chen et al., 2014).  
Many targets for influenza vaccine-development have been investigated, 
including those inducing T cell and/or B cell responses; e.g. the highly 
conserved "stalk" domain of HA, termed HA2 (Khanna et al. 2014). 
Other evidence has implicated nucleoprotein (NP) and Matrix 1 (M1) as 
vaccine targets capable of inducing cross protection via enhanced T cell 
activation (Antrobus et al., 2013a). 
Another potential vaccine target is influenza matrix protein 2 (M2e). 
Initially this seemed highly conserved and induced broadly-acting anti-
bodies. However, over 20 variants of M2e were later identified in newly 
emerging influenza A strains, raising questions over its usefulness as a 
"universal" vaccine. Nevertheless, regions of M2e may still be useful for 
inducing broadly acting protection (Gottlieb & Ben-Yedidia, 2014). 
Conserved targets would be useful in formulating a "universal" vaccine, 
as they would cover multiple viral subtypes (Brown & Kelso, 2009). 
Such "universal" vaccine design can potentially be addressed by a T-cell 
epitope ensemble vaccine comprising short, highly conserved, immuno-
genic peptides from influenza able to activate T cells. Some epitope-
based influenza vaccines are already in clinical trials. One, Multimeric-
001, which consists of a single recombinant protein composed of B and 
T cell epitopes, is seen to induce both cellular and humoral immunity 
(Gottlieb & Ben-Yedidia, 2014; Atsmon et al., 2014). Although such 
trials have been small, they are promising, inducing cross protective 
immunity without severe side effects. 
We address here the design of epitope ensemble vaccines that have wide 
coverage of the human population in terms of HLA binding and wide 
coverage of different viral subtypes. Such an approach draws strong 
support from both theoretical studies (Schubert et al., 2013) and from a 
wealth of recent experimentally-verified vaccines developed with con-
cordant goals, including inter alia filoviruses (Fenimore et al., 2012), 
HIV (Ondondo et al., 2016), Dengue (Nascimento et al., 2013), Survivin 
(Hoffman et al., 2015), and Metapneumovirus (Li et al., 2015). 
In what follows, we expand on an emerging paradigm within rational 
vaccine design (Molero-Abraham et al., 2013) to include class II 
epitopes, and identify multiple, conserved influenza A T cell epitopes 
that together comprise putative non-seasonal flu vaccines. 
2 Methods 
Collection of influenza A specific Epitopes Influenza A CD8+ and 
CD4+ T cell epitopes known to induce immune responses during natural 
infection were initially collected from the Immune Epitope Database and 
Analysis Resource [IEDB] (Peters et al., 2005). Inclusion criteria re-
stricted the data to peptides giving positive T-cell assay results and that 
were restricted by human HLA molecules. In addition, for CD8+ 
epitopes we only considered those with 9 residues because most known 
epitopes processed by class I HLA are 9-mers (Reche et al., 2004). 
Collection, Clustering and Multiple Sequence Alignment of Influen-
za A Polyproteins 
To generate a multiple sequence alignment (MSA), full length influenza 
A polyproteins were collected from the Influenza Viral Resource at the 
National Centre for Biotechnology Information [NCBI] (Bao et al., 
2008) and Influenza Research Database (Squires et al., 2012). Identical 
sequences were removed as unwanted repetition may lead to bias when 
identifying conserved regions. To ensure inclusion of full length proteins 
only, incomplete sequences were omitted. Sequence sets corresponding 
to 12 different influenza A specific proteins were processed: each was 
submitted to two clustering web servers to remove redundant sequences: 
BLASTclust (http://toolkit.tuebingen.mpg.de/blastclust) (Altschul et al., 
1990) and CD-HIT (http://weizhong-lab.ucsd.edu/cdhit_suite/cgi-
bin/index.cgi?cmd=cd-hit) (Fu et al., 2012). To reduce sequence bias, 
the two clustering servers were used separately in two repeated cycles. 
Sequences for each influenza A protein type were clustered with 96-99% 
sequence similarity. Once clustered, MSA outputs were created using the 
multiple sequence alignment package MUSCLE (Edgar, 2004).  
Variability Analysis of Influenza A Polyproteins 
For each influenza protein, MSA data were subjected to sequence varia-
bility analysis using the Protein Variability Server [PVS] (Garcia-
Boronat et al., 2008). We selected the Shannon entropy (H) as the varia-
bility metric (Stewart et al., 1997) and a variability threshold of 0.5. 
Shannon Entropy values range from 4.3 (all amino acids equally repre-
sented at a site) to 0.0 (invariant site with only one allowed residue). As 
a result, we obtained consensus sequences with variable positions, H > 0, 
masked. Subsequently, we selected as conserved epitopes those that 
matched precisely over their entire length with the generated consensus 
sequences. Thereby, we retained only those epitopes in which no amino-
acid position had H > 0.5.  
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Calculation of Population Protection Coverage 
The PPC of T cell epitope ensembles equals the cumulative phenotypic 
frequency of the HLA alleles restricting the T cell epitopes and can be 
computed using the genetic frequencies of the relevant HLA alleles 
within the population. In this study, the PPC of HLA I-restricted epitopes 
was calculated using EPISOPT v.1 
(http://imed.med.ucm.es/EPISOPT.html) and the IEDB PPC prediction 
tool (http://tools.immuneepitope.org/tools/population/iedb_input). 
EPISOPT computes PPC in one step after predicting epitope-HLA I 
binding profiles using HLA I frequencies for the 5 main ethnic groups 
present in the USA population (Black, Caucasian, Hispanic, Asian and 
native North American) (Cao et al., 2001). The IEDB tool requires man-
ual entry of HLA I binding profiles which we first obtained using the 
IEDB class I HLA binding prediction server 
(http://tools.immuneepitope.org/mhci/). A class I HLA reference set was 
used as these alleles were frequently found in the population (Weiskopf 
et al., 2013). This allowed a PPC to be calculated for class I HLA data of 
the world's population rather than just the five USA ethnicities. Class I 
HLA binding profiles included all those alleles that were predicted to 
bind the peptide for the top 1% percentile rank for all peptides in the 
relevant antigen. 
For each CD4+ T epitopes, we predicted HLA II binding affinities to 
different alleles found in the human population (Greenbaum et al., 2011) 
using IEDB (http://tools.immuneepitope.org/mhcii/). Many other predic-
tion methods are available (Soria-Guerra et al., 2015). We used a 10% 
percentile rank cutoff to select the targeted alleles. These were then 
submitted to the IEDB PPC tool, allowing calculation of PPC for the 
world population rather than specific ethnicities. 
3 Results 
We collected from the IEDB 210 CD8+ and 816 CD4+ T cell influenza 
A-specific epitopes, of length 8-18 residues, known to be targeted during 
natural infection. We also collected influenza A proteins and clustered 
them using BLASTclust and CD-HIT (details in Material and Methods), 
obtaining two different cluster sets, and two different sets of conserved 
regions, one from BLASTclust and the other from CD-HIT. We used 
these conserved regions to identify matching conserved T cell epitopes. 
 
Table 1. PPC values for class I epitopes  
Epitope Profile PPC (%)   Antigen 
FMYSDFHFI 
 
 
GILGFVFTL 
 
SVKEKDMTK 
   
ILRGSVAHK 
FYIQMCTEL 
ILKGKFQTA 
GMDPRMCSL 
YYLEKANKI 
RGINDRNFW 
TQIQTRRSF 
DTVNRTHQY 
 
A0201 A0202 A0203 A0204 A0205 
A0206 A0214 A2402 B4402 B5301 
B5401 
A0201 A0202 A0203 A0204 A0205  
A0206 A0207 A0209 A0214 C0304 
A0301 A1101 A3101 A3301 A6801 
B1513 
A0203 A0301 A1101 A3301 A6801 
A2402 B1509 C0702 
A0202 A0203 A0206 A0209 B0801 
A0203 A2402 B0801 
A0214 B3801 B39011 
B1513 B5701 B5702 
B5701 
A6601 B5702 B5801 
 
56.41 
 
 
40.74 
 
32.18 
 
28.16 
22.05 
14.81 
14.18 
3.92 
2.48 
1.93 
1.53 
 
  PA 
 
 
M1 
 
PA 
 
NP 
NP 
NP 
NP 
PA 
NP 
PB1 
PB1 
 
Table 1 lists identified 9-mer CD8+ epitopes able to induce a T cell response 
against influenza A. Each epitope's individual PPC and HLA class II allelic binding 
restriction is also given. Only epitopes with non-negligible PPCs are shown. 
First, we examined CD8+ T cell epitopes, identifying 11 conserved 
epitopes common to both sets of conserved regions. Additionally, two 
extra epitopes were identified in the BLASTclust set (GILGFVFTL, 
IRHENRMVL) and another two from CD-HIT (RGINDRNFW, 
YINTALLNA). EPISOPT was used to select CD8+ T cell epitopes for 
our USA-specific vaccine. Table 1 lists calculated non-zero PPC values 
for CD8+ epitopes generated by the server.  
To reach a PPC >80% a minimum of two epitopes were needed. To 
achieve a PPC >95% at least 6 epitopes are required. EPISOPT identi-
fied 4 different combinations of which two combinations reached a PPC 
of 95.69% and the other two 95.36%. We selected set one to define the 
CD8+ arm of our USA-specific ensemble vaccine.  
We collected 816 influenza A CD4+ T cell epitopes from the IEDB 
database and selected 7 conserved CD4+ T cell epitopes by comparing 
with the   conserved regions identified by BLASTClust and CD-HIT 
clustering routes were used.. These conserved epitopes of varying amino 
acid length were submitted to IEDB the class II HLA binding prediction 
tool. See table 2. Many epitopes did not bind to any alleles within the top 
10% percentile rank and of those that did only one epitope, 
TGTGYTMDTVNRTHQ, was identified by both BLASTclust and CD-
HIT. Three additional epitopes were identified by BLASTclust 
(KGILGFVFTLTVPSE, ILGFVFTLTVPSERG, and 
NPLIRHENRMVLAST) and three by CD-HIT 
(TYQRTRALVRTGMDP, MAFLEESHPGIFENS, and 
EYIMKGVYINTALLN).  
 
Table 2. PPC values for Class II epitopes 
Epitope Profile PPC (%) Antigen 
KGILGFVFT
LTVPSE 
 
 
 
 
 
EYIMKGVYI
NTALLN 
 
 
 
 
NPLIRHENR
MVLAST 
 
 
ILGFVFTLT
VPSERG 
 
 
 
 
 
 
TGTGYTMD
TVNRTHQ 
TYQRTRAL
VRTGMDP 
MAFLEESH
PGIFENS 
 
    DPA1*01/DPB1*04:01 DRB1*11:01 
DPA1*03:01/DPB1*04:02 DRB1*04:05 
DPA1*02:01/DPB1*14:01 DRB1*04:01 
DPA1*01:03/DPB1*02:01 DRB1*08:02 
DQA1*04:01/DQB1*04:02 DRB5*01:01 
DPA1*02:01/DPB1*05:01 DRB1*07:01 
DRB1*15:01 DRB1*03:01 
    DQA1*01:02/DQB1*06:02 DRB1*08:02 
DPA1*02:01/DPB1*01:01 DRB3*01:01 
DPA1*03:01/DPB1*04:02 DRB1*11:01 
DPA1*01:03/DPB1*02:01 DRB1*04:05 
DRB5*01:01 DRB1*04:01 DRB1*15:01 
DRB1*03:01  DRB1*12:01 DRB1*13:02 
    DRB1*03:01 DRB3*02:02 DRB1*08:02 
DRB1*15:01 DQA1*01:02/DQB1*06:02 
DRB1*09:01 DRB1*04:01 DRB1*13:02 
DRB3*01:01 DRB1*11:01 
    DPA1*01/DPB1*04:01 DRB1*11:01 
DPA1*03:01/DPB1*04:02 DRB1*04:05 
DPA1*02:01/DPB1*14:01 DRB1*04:01 
DQA1*04:01/DQB1*04:02 DRB5*01:01 
DRB1*07:01 DRB1*08:02 
DQA1*05:01/DQB1*02:01 DRB1*03:01 
DRB3*02:02 DRB1*09:01 
DPA1*01:03/DPB1*02:01 
    DRB3*01:01 DRB1*03:01 DRB1*04:01 
DRB3*02:02 
    DRB5*01:01 DRB1*07:01 DRB1*11:01 
DRB3*02:02 
    DRB3*01:01 DRB1*13:02 DRB1*09:01 
 
     
66.92 
 
 
 
 
 
 
62.27 
 
 
 
 
 
61.62 
 
 
 
   59.12 
 
 
 
 
 
 
 
27.97 
 
27.73 
 
12.87 
 
 
 M1 
 
 
 
 
 
 
PA 
 
 
 
 
 
M1 
 
 
 
M1 
 
 
 
 
 
 
 
PB1 
 
NP 
 
PB1 
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Summary of selected CD4+ epitopes, with their predicted class II binding re-
strictions and PPC.  
 
All epitope-HLA II binding profiles were then entered into the IEDB 
PPC tool for analysis. NPLIRHENRMVLAST, 
TGTGYTMDTVNRTHQ, TYQRTRALVRTGMDP, and 
MAFLEESHPGIFENS have class II HLA binding profiles that are com-
pletely covered by the other three remaining epitopes and therefore they 
were not considered when calculating PPC with multiple CD4+ T cell 
epitopes. The remaining three CD4+ T cell epitopes gave a combined 
PPC of 76.38%. The resulting combination of selected CD8+ and CD4+ 
epitopes form a population-weighted potential candidate USA-specific 
multiple epitope ensemble vaccine capable of inducing region-specific 
cross protection against influenza A (Table 3). 
 
Table 3. Components of USA-specific vaccine 
Epitope Profile PPC (%)  Antigen 
GILGFVFTL 
 
FMYSDFHFI 
 
 
GMDPRMCSL 
SVKEKDMTK 
 
FYIQMCTEL 
DTVNRTHQY 
KGILGFVFTL
TVPSE  
 
 
 
 
 
EYIMKGVYIN
TALLN 
 
 
 
 
ILGFVFTLTV
PSERG 
   A0201 A0202 A0203 A0204 A0205  
   A0206 A0207 A0209 A0214 C0304 
   A0201 A0202 A0203 A0204 A0205 
   A0206 A0214 A2402 B4402 B5301 
   B5401 
   A0203 A2402 B0801 
   A0301 A1101 A3101 A3301 A6801 
    B1513 
   A2402 B1509 C0702 
   A6601 B5702 B5801 
    DPA1*01/DPB1*04:01 DRB1*11:01 
DPA1*03:01/DPB1*04:02 DRB1*04:05 
DPA1*02:01/DPB1*14:01 DRB1*04:01 
DPA1*01:03/DPB1*02:01 DRB1*08:02 
DQA1*04:01/DQB1*04:02 DRB5*01:01 
DPA1*02:01/DPB1*05:01 DRB1*07:01 
DRB1*15:01 DRB1*03:01 
DQA1*01:02/DQB1*06:02  
    DRB1*08:02  DPA1*02:01/DPB1*01:01 
DRB3*01:01 DPA1*03:01/DPB1*04:02 
DRB1*11:01 DPA1*01:03/DPB1*02:01 
DRB1*04:05 DRB5*01:01 DRB1*04:01 
DRB1*15:01 DRB1*03:01 DRB1*12:01 
DRB1*13:02 DPA1*01/DPB1*04:01 
DRB1*11:01 DPA1*03:01/DPB1*04:02 
DRB1*04:05 DPA1*02:01/DPB1*14:01 
DRB1*04:01 DQA1*04:01/DQB1*04:02 
DRB5*01:01 DRB1*07:01 DRB1*08:02 
DQA1*05:01/DQB1*02:01 DRB1*03:01 
DRB3*02:02 DRB1*09:01 
DPA1*01:03/DPB1*02:01 
40.7 
 
56.4 
 
 
14.2 
32.2 
 
22.2 
1.5 
66.9 
 
 
 
 
 
 
62.3 
 
 
 
 
 
59.1 
 M1 
 
PA 
 
 
NP 
PA 
 
NP 
PB1 
M1 
 
 
 
 
 
 
PA 
 
 
 
 
 
M1 
Table 3 lists the CD8+ and CD4+ epitopes comprising our USA-specific vaccine, 
together with origin, individual PPC and HLA class II allelic binding restriction.  
 
To derive the equivalent universal vaccine, the class I HLA binding 
profiles of each epitope were predicted using the IEDB class I HLA 
binding prediction tool. We then used the IEDB PPC tool to estimate 
PPC values against the world population, rather than the North Ameri-
can-only coverage provided by EPISOPT. GMDPRMCSL, 
YINTALLNA and IRHENRMVL were excluded as they did not bind to 
any class I HLA allele within the top 1% percentile rank. Excluding 
those epitopes that gave a PPC of 0%, a maximum PPC of 91.04% was 
possible with the remaining 12 CD8+ epitopes. This was different result 
to EPISOPT v.1, where just 6 epitopes gave a PPC >95%. This reflects 
the lesser diversity within the North America population compared to the 
world population as a whole. Epitopes which gave an individual PPC 
>10% using the IEDB PPC tool were considered; and together reached a 
PPC value of 90.22%. These constituted the CD8+ component of our 
universal influenza vaccine. See table 4. The selected CD4+ and CD8+ 
epitopes were combined together to calculate a PPC against both class I 
HLA and class II  HLA alleles against the world's population using the 
IEDB PPC tool. See Table 4. A total PPC of 97.69% was achieved. The 
selected T cell epitopes form a population-weighted potential multiple 
epitope ensemble vaccine able to induce broad, global, cross-protection 
against influenza A 
 
 
Table 4. Components of universal vaccine 
Epitope Profile PPC (%) Antigen 
GILGFVFTL 
 
FMYSDFHFI 
 
 
ILRGSVAHK  
FYIQMCTEL 
ILKGKFQTA 
YYLEKANKI  
VSDGGPNLY 
YSHGTGTGY 
KGILGFVFTL
TVPSE  
 
 
 
 
 
EYIMKGVYIN
TALLN 
 
 
 
 
ILGFVFTLTV
PSERG 
    A0201 A0202 A0203 A0204 A0205  
    A0206 A0207 A0209 A0214 C0304 
    A0201 A0202 A0203 A0204 A0205 
    A0206 A0214 A2402 B4402 B5301 
    B5401 
    A0203 A0301 A1101 A3301 A6801 
    A2402 B1509 C0702 
    A0202 A0203 A0206 A0209 B0801 
    A0214 B3801 B39011 
    A0101 A3002 
    A0101 A2601 B1502 
    DPA1*01/DPB1*04:01 DRB1*11:01 
DPA1*03:01/DPB1*04:02 DRB1*04:05 
DPA1*02:01/DPB1*14:01 DRB1*04:01 
DPA1*01:03/DPB1*02:01 DRB1*08:02 
DQA1*04:01/DQB1*04:02 DRB5*01:01 
DPA1*02:01/DPB1*05:01 DRB1*07:01 
DRB1*15:01 DRB1*03:01 
    DQA1*01:02/DQB1*06:02 DRB1*08:02 
DPA1*02:01/DPB1*01:01 DRB3*01:01 
DPA1*03:01/DPB1*04:02 DRB1*11:01 
DPA1*01:03/DPB1*02:01 DRB1*04:05 
DRB5*01:01 DRB1*04:01 DRB1*15:01 
DRB1*03:01  DRB1*12:01 DRB1*13:02 
    DPA1*01/DPB1*04:01 DRB1*11:01 
DPA1*03:01/DPB1*04:02 DRB1*04:05 
DPA1*02:01/DPB1*14:01 DRB1*04:01 
DQA1*04:01/DQB1*04:02 DRB5*01:01 
DRB1*07:01 DRB1*08:02 
DQA1*05:01/DQB1*02:01 DRB1*03:01 
DRB3*02:02 DRB1*09:01 
DPA1*01:03/DPB1*02:01 
 
42.7 
 
49.5 
 
 
20.4 
26.2 
10.6 
26.2 
19.6 
29.2 
66.9 
 
 
 
 
 
 
62.3 
 
 
 
 
 
59.1 
 M1 
 
PA 
 
 
NP 
NP 
NP 
PA 
PB1 
PB1 
M1 
 
 
 
 
 
 
PA 
 
 
 
 
 
M1 
Table 4 lists the CD8+ and CD4+ epitopes comprising our global vaccine, together 
with origin, individual PPC and HLA class II allelic binding restriction. 
We have intentionally not specifically targeted subtypes. However, due 
to their wide sequence conservation, the identified epitopes are well 
represented across most major subtypes. Apart from subtypes of influen-
za A unique to bats, there are 16 haemagglutinin and 9 neuraminidase 
subtypes transmissible to humans making 144 possible H*N* combina-
tions, of which 128 have been observed in the wild, as indicated by the 
presence of at least one designated sequence in the Influenza Virus Re-
source  (Bao et al., 2008), as of February 2016. BLASTing each of our 9 
USA-specific vaccine epitopes against Orthomyxoviridae (txid:11308) 
sequences within the non-redundant NCBI protein database, generated 
sets of 100% identical matches to sequences from distinct H*N* sub-
types, ranging in number from 95 H*N* subtypes (GILGFVFTL) to 111 
subtypes (SVKEKDMTK). As a whole, the USA-specific vaccine has 
Universal influenza vaccine 
sequence matches to a total of 117 distinct H*N* sub-types. This indi-
cates that the vaccine has a high coverage (95%) of observed influenza 
subtypes. BLASTing the 11 universal vaccine epitopes against Or-
thomyxoviridae sequences, produced 100% identical matches to distinct 
H*N* subtypes, which ranged in number from 93 
(KGILGFVFTLTVPSE) to 108 (FMYSDFHFI). The universal vaccine 
matches 113 H*N* sub-types, again indicating a high overall coverage 
(88%) of observed subtypes. Identifying additional highly subtype-
specific conservation might enhance our putative universal Influenza A 
vaccine further, as adding a cocktail of strain-specific epitopes may 
strengthen cross-protection within our putative epitope ensemble. 
It is clear that a vaccine based on a single epitope would not provide 
universal protection against heterosubtypic influenza A strains. Fenoglio 
et al. (2015) concluded that a multiple peptide based vaccine leads to 
increased T cell responses when compared to single peptide vaccines, 
reinforcing the need to examine multiple conserved epitopes. Individual-
ly, no single peptide gave a PPC greater >90% however, such values 
were achieved when combining epitopes. It is evident from a comparison 
of EPISOPT and IEDB that generated PPC values are method-
dependent, with alternative allele frequencies and calculation strategies 
yielding different values. Nonetheless, high consensus values, as derived 
here, indicate the value of this approach as a fully-validated starting 
point for vaccine design. Ideally, epitopes with a broad allele specificity 
would be assayed experimentally against well-understood alleles repre-
sentative of class I and class II supertypes (Doytchinova and Flower, 
2005; Doytchinova et al., 2005).  
All T cell epitopes included in the final vaccine combination were either 
part of polymerase acidic protein (PA), nucleoprotein (NP), matrix 1 
protein (M1) or polymerase basic protein 1 (PB1). The large PPC value 
found for GILGFVFTL located on M1 protein is not surprising as previ-
ous research concluded it was broadly recognized by the population 
(Alexander et al., 2010). It is known to be immunodominant when re-
stricted by HLA-A02 and other evidence suggests degenerate recognition 
by CTL when restricted by HLA-C08 (Choo et al., 2014).  In cellular 
immunity, immunodominance refers to the observation that while many 
peptides can be presented by host cells, a larger portion of T cells focus 
their attention on a very limited number of HLA-presented peptides. 
Such evidence, together with our results, supports the view that the 
epitope will be useful in providing broad protection against distinct 
influenza A strains. 
NP has long been considered a viable option for inducing cross protec-
tive CTL in humans and mice; many studies have sought to ensure NP-
based vaccines are immunogenic enough to be cross protective. These 
include priming with DNA vaccines containing NP (Epstein et al., 2005) 
alone or combined with other conserved proteins such as NS1 and M1 
(Zhirnov et al., 2007) followed by boosting with recombinant NP de-
rived from E coli. In animal models, all show promise, with cross-
reactive T cell responses against influenza A subtypes observed at many 
levels. A vaccine consisting of modified vaccinia virus Ankara vector, 
M1, and NP (MVA-NP+M1) has also been tested in clinical trials in-
volving healthy adults (Huang et al., 2012). The MVA-NP+M1 vaccine 
yields much higher T cell responses compared to other influenza vac-
cines, as well as being safe in animal models and human trials. T cell 
responses were boosted when combined with seasonal vaccination com-
pared to seasonal vaccination alone suggesting seasonal vaccines may 
still prove a useful component in future universal vaccines (Berthoud et 
al., 2011; Antrobus et al., 2013a). 
Alexander et al. (2008) also identified FMYSDFHFI, FYIQMCTEL, 
YYLEKANKI, GILGFVFTL and YSHGTGTGY as CD8+ epitopes for 
use in cross protective vaccines. Similar to our results, each binds exten-
sively within a particular class I HLA supertype: FMYSDFHFI, A2; 
FYIQMCTEL, A24; YYLEKANKI, A24; GILGFVFTL, A2 and 
YSHGTGTGY, A1. These epitopes were conserved in over 93% of 69 
distinct influenza strains and 100% conserved in 10 swine flu H1N1 
strains. All these epitopes produce good CTL responses in donors ex-
pressing the relevant class I HLA alleles. The similarity of derived 
epitopes coupled to their high conservation among a diverse group of 
influenza A strains, suggests such epitopes will prove viable targets for 
future influenza A epitope vaccine formulations. 
None of these highly conserved CD8+ or CD4+ T cell epitopes were 
found in hemagglutinin (H) or neuraminidase (N). While it is often as-
sumed wrongly that H or N epitopes are all important, this is not the case 
with T-cell responses. While N and H are the key proteins for antibody 
binding, cellular immunity can respond to viral infection before viral 
shedding, opening the whole influenza genome to immune surveillance. 
The absence of N and H epitopes is explained by the low sequence con-
servation between different strains (Chen & Deng, 2009), due to the 
highly variable antigen binding sites that allow antibody immune eva-
sion.  
Recent studies suggest immunodominant influenza epitopes are less 
conserved generally than their subdominant counterparts, which is 
thought to result from immune pressure (Chen et al., 2014). Immu-
nodominant epitopes are likely to give the greatest immune response. 
Some of our epitopes may be subdominant potentially reducing their 
ability to induce potent immune responses. However, immunodominance 
hierarchies are dynamic and can be altered by vaccination (Welsh et al., 
2010). Any peptide that is efficiently processed and presented in both 
target and antigen-presenting cells are good candidates for vaccines 
regardless of their immunodominance. Only subdominance resulting 
from failures of processing or from poor binding to MHCs would lead to 
an ineffective vaccine. However, the epitopes we selected are likely to be 
processed in vivo as they are known to be targeted during a natural infec-
tion and exhibit high predicted MHC binding. 
While the performance of many class I binding algorithms has recent 
improved significantly, class II predictions remain poor or inconsistent 
(Lafuente & Reche, 2009). Since class II HLA have open-ended binding 
sites, they can bind peptides with a much broader length distribution than 
class I. The lower quality performance compared to class I HLA predic-
tion increases the likelihood of identifying false-positive CD4+ T cell 
epitopes (Nielsen et al., 2010). In this study, CD8+ epitopes were re-
stricted to 9-mer epitopes, even though class I HLA molecules can pre-
sent a significant number of peptides of other lengths (MacDonald et al., 
2010). Although most known class I HLA specific peptides are 9-mers, 
and class I HLA binding predictions of peptides of other lengths are not 
as reliable (Lundegaard et al., 2010), many immunogenic CD8+ epitopes 
of length other than 9 are known: for example, Alexander et al. (2010) 
identified multiple 10-mer, influenza A specific CD8+ epitopes. Future 
studies might therefore usefully include epitopes of different lengths. 
The list of epitopes identified here does not, in itself, constitute the en-
tirety of a deployable vaccine.  Constructing a multiple epitope ensemble 
vaccine is often problematic as they are seldom sufficiently immunogen-
ic. Short peptides suffer from poor immunogenicity and therefore vac-
cines require additional components to help initiate T cell responses. 
Epitopes must be delivered, packaged into a stable vaccine formulation 
(Yand and Kim, 2015). Epitopes can be delivered as poly-epitope pep-
tide(s) or as part of a viral vector. In either case, the order of epitopes 
and the presence of cleavage sites, etc. is crucial. Schubert and 
Kohlbacher (2016) have, for example, addressed how to optimize this 
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process. The typical lack of immunogenicity of such constructs is nota-
ble (Mahanty et al., 2015), and much empirical work - including optimiz-
ing the number and timings of vaccination - is necessary to address this 
(De Groot et al., 2005a,b). The main way to do address this is by addi-
tion of adjuvants to the formulation (Bayry et al., 2008).  
Our approach has focused on designing the so-called biological compo-
nent of a vaccine, the part responsible - through molecular recognition 
events - for engendering the specificity of vaccine responses. Beyond 
this, as methodology progresses, issues both conceptual and practical 
will need to be addressed. These include the synergistic orchestration of 
both the mechanistic targeting and/or co-uptake of vaccine components 
and the optimal logistics of vaccination protocols, including chosen 
regimen and the size, number, and frequency of vaccinations (Moyer et 
al., 2016). In this regard, computational modelling frameworks have 
much to offer, allowing us to predict overall immune system response 
dynamics and pharmacokinetics that should allow us to optimise 
memory effects and the dosing of vaccine administration (Pappalardo et 
al., 2014). 
4 Conclusion 
A "universal" vaccine would ideally induce immunity against all or most 
influenza A subtypes. However, as influenza continually evolves, formu-
lating a vaccine with such broad protection remains problematic. Current 
seasonal influenza vaccines lack the ability to induce cellular immunity 
and instead induce strain specific humoral immunity where novel or 
differing influenza strains can easily bypass immune recognition. In this 
study, multiple, conserved T cell epitopes were identified using im-
munoinformatics. The combination of epitopes identified here should be 
able to induce broad heterosubtypic, protection against influenza A 
across the global population (PPC= 97.7%) or in geographically-
restricted populations, in this case the USA (PPC=96.3%). Our putative 
vaccines contain both CD8+ and CD4+ epitopes, as both types of T cells 
play important roles in viral clearance. Although all identified epitopes 
are known to be immunoreactive, further studies are needed to assess 
their efficacy. The extent of cross protection will require further analysis 
to verify the efficacy against particular influenza A subtypes. Despite 
these limitations the results are a promising vindication of our approach, 
and the extensions we detail, should prove of interest in future influenza 
vaccination strategies.  
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